Fulcrum Thera

$14.33 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Fulcrum Thera

Fulcrum Therapeutics, Inc. clinical-stage biopharmaceutical company. The Company focuses on improving the lives of patients with genetically defined rare diseases. The Company have developed a product engine which identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The Company is also engaged in developing drugs for the treatment for the root cause of muscle disorders, central nervous system disorders and blood disorders. The Company is using Its proprietary product engine to identify and validate drug targets and develop product candidates to address diseases caused by the mis-expression of certain genes. Its product candidate includes losmapimod, is a small molecule that is developed for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, is a small molecule designed to bind embryonic ectoderm development (EED).

Stock Analysis

last close $15.06
1-mo return -36%
3-mo return -43%
avg daily vol. 497.68T
52-week high 33.1
52-week low 6.85
market cap. $611M
forward pe -
annual div. -
roe -44.7%
ltg forecast -
dividend yield -
annual rev. $18M
inst own. 90.2%
baraka

Subscribe now for daily local and international financial news

Subscribe